JUP Announces 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance

• Jupiter Neurosciences implemented a 1-for-75 reverse stock split to regain Nasdaq compliance.
• The structural change reduces outstanding shares from approximately 57.8 million to roughly 770,081 without altering underlying operations.
• Split-adjusted trading commenced on August 7, 2026, under the ticker JUNS with a new CUSIP number.
• The move aims to stabilize the market position of the clinical-stage biopharmaceutical firm amid prolonged low bid prices.

Jupiter Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on neurological and neurodegenerative disorders, has executed a 1-for-75 reverse stock split. This significant corporate action was approved by the board of directors and subsequently ratified by stockholders at the annual meeting held on July 22, 2026 . The reverse split legally took effect at 4:01 p.m. Eastern Time on August 6, 2026, marking a pivotal moment in the company's efforts to maintain its listing on The Nasdaq Capital Market .

The primary objective of this consolidation is to increase the per-share trading price to meet the minimum bid price requirement for continued listing eligibility . By adjusting the equity structure, the company seeks to preserve investor access and stabilize its market position after shares traded as low as $0.08 over the past year . This structural adjustment is designed to mitigate the risks associated with prolonged low bid prices and potential delisting .

How Does the 1-for-75 Split Affect Shareholders?

The mechanics of the reverse split involve converting every 75 existing shares of common stock into one new share . This dramatic reduction in share count decreased the total number of outstanding common shares from approximately 57,756,143 as of August 4, 2026, to approximately 770,081 shares . The total number of authorized shares remained unchanged, ensuring that the company retains flexibility for future capital raises or option exercises .

Fractional shares resulting from the conversion were not issued to shareholders . Instead, stockholders entitled to fractional shares received cash payments equivalent to the fractional share's value . These payments were calculated based on the closing sales price of the common stock on the trading day immediately prior to the effective date, August 6, 2026 . This cash-in-lieu mechanism ensures that shareholders receive fair value for their proportional ownership despite the inability to hold fractional equity .

Trading on a split-adjusted basis began on August 7, 2026, under the current ticker symbol "JUNS" . The company also implemented a new CUSIP number, 48208B 302, to reflect the structural changes to its equity . This administrative update facilitates accurate tracking and settlement of the newly consolidated shares in the market .

What Are the Implications for Liquidity and Market Position?

While the reverse split aims to stabilize the stock price, it may impact liquidity and ownership perception among investors . The reduction in outstanding shares from nearly 58 million to under 800,000 significantly alters the market dynamics of the stock . Lower float sizes can sometimes lead to increased volatility, as fewer shares are available for trading . However, the company maintains that the move is necessary to align its equity profile with exchange standards .

The restructured capital base does not alter the company's underlying operations or financial results . Jupiter Neurosciences continues to advance its clinical pipeline, including the lead program JOTROL for Parkinson’s disease . The company is also developing ALA-002, a psychedelic candidate for treatment-resistant PTSD, while maintaining its commercial longevity supplement, Nugevia . These operational fundamentals remain the primary drivers of long-term value, independent of the share consolidation .

The move to regain Nasdaq compliance is critical for maintaining institutional investor access and market visibility . Failure to meet minimum bid price requirements can lead to delisting proceedings, which would severely restrict trading options for shareholders . By proactively addressing this requirement, Jupiter Neurosciences aims to provide a more stable environment for its investors . The company's market capitalization stands at approximately $5.09 million, reflecting the current valuation of its consolidated equity .

Investors should note that while the reverse split addresses listing compliance, it does not guarantee future stock performance . The company's clinical progress and commercial execution will ultimately determine its long-term success . The structural change is a defensive measure to preserve the platform for future growth and development .

Jupiter Neurosciences remains focused on developing innovative therapies for neurological disorders while navigating the complexities of public market requirements . The 1-for-75 reverse split represents a strategic step to ensure continued eligibility for trading on a major U.S. exchange . As the company advances its pipeline, stakeholders will monitor how this structural adjustment impacts liquidity and market perception .

The implementation of the split underscores the challenges faced by clinical-stage biopharmaceuticals in maintaining exchange compliance . Jupiter Neurosciences has taken decisive action to align with Nasdaq standards while preserving its operational focus . The coming months will reveal how this change influences investor confidence and trading activity for the JUNS ticker .